COVID-19: For information related to COVID-19 (formerly referred to as “novel coronavirus"), visit

VCU Massey Cancer Center


Molecules to Medicines (M2M) Pilot Program

Current Call for Applications: 

The intent of this award is to promote cancer research collaborations between biologists and organic synthetic or medicinal chemists to generate chemical probes that will eventually lead to anticancer drugs. The application should be a multi-principal investigator (MPI) collaboration with both a chemist and biologist serving as PIs.

The focus of this award must be on the following elements: 

  • Designing novel compounds using structure-based drug design or identifying hits through HTS
  • Performing hit-to-lead optimization and structure activity relationship studies
  • Using the lead small molecules/compounds/chemicals to probe aberrant cellular pathways in tumor cells
  • Studying the mechanism by which these chemical probes affect proliferation, survival, invasion and other hallmarks of cancer in cell culture, patient-derived organoids and xenografts, as well as other cancer-related animal models
  • Confirming that the compounds developed have antitumor activity as demonstrated in efficacy studies using relevant animal models

*Final Applications DUE: December 15, 2020


Upcoming Cycle Dates: Future deadlines and award timeframes will be posted here as soon as confirmed. Thank you for your interest.  

*Interested researchers or for assistance accessing related program information, please contact:

Olivia Patterson 
Training and Education Coordinator
VCU Massey Cancer Center 
Phone: (804) 628-3400